Related Experiment Video For Cytology
Updated: Jan 26, 2026

Quantitative Immunoblotting of Cell Lines as a Standard to Validate Immunofluorescence for Quantifying Biomarker Proteins in Routine Tissue Samples
Published on: January 7, 2019
Development and Validation of Molecular Assays for Limited Tissue Samples
Robyn Sussman1, Jason N Rosenbaum2
1Center for Personalized Diagnostics, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abstract:
As the value of molecular testing of cancer specimens increases, the number of tests imposed on tumor specimens also increases, often in tension with the amount of tumor material available. To develop and validate molecular assays for limited specimens, there are specific concerns that must be addressed, including DNA quality, quantity, and abundance; the number of targets/ability to multiplex; and the analytical sensitivity and specificity of the assay itself. Ultimately, weighing these considerations during assay validation in the overall context of clinical utility and laboratory workflow is critical for delivering the highest level of personalized care to patients.
Related Concept Videos
Limiting Reactant
In Vitro Drug Release Testing: Overview, Development and Validation
Reliability and Validity
The Number e as a Limit
Data Validation
Nursing assessment guides are generally based on holistic models rather than medical...
Data Validation
Key parameters for method validation include:

